Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 37
Filtrar
Más filtros

Banco de datos
País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Med Intensiva ; 41(3): 174-187, 2017 Apr.
Artículo en Inglés, Español | MEDLINE | ID: mdl-28062169

RESUMEN

Plasmapheresis is an extracorporeal technique that eliminates macromolecules involved in pathological processes from plasma. A review is made of the technical aspects, main indications in critical care and potential complications of plasmapheresis, as well as of other extracorporeal filtration techniques such as endotoxin-removal columns and other devices designed to eliminate cytokines or modulate the inflammatory immune response in critical patients.


Asunto(s)
Cuidados Críticos/métodos , Hemoperfusión , Plasmaféresis , Humanos , Plasmaféresis/efectos adversos
2.
Transpl Infect Dis ; 17(2): 221-33, 2015 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-25652036

RESUMEN

BACKGROUND: Umbilical cord blood transplantation (CBT) is an established alternative source of stem cells in the setting of unrelated transplantation. When compared with other sources, single-unit CBT (sCBT) is associated with a delayed hematologic recovery, which may lead to a higher infection-related mortality (IRM). Co-infusion with the sCBT of CD34+ peripheral blood stem cells from a third-party donor (TPD) (sCBT + TPDCD34+) has been shown to markedly accelerate leukocyte recovery, potentially reducing the IRM. However, to our knowledge, no comparative studies have focused on severe infections and IRM with these 2 sCBT strategies. METHODS: A total of 148 consecutive sCBT (2000-2010, median follow-up 4.5 years) were included in a multicenter retrospective study to analyze the incidence and risk factors of IRM and severe viral and invasive fungal infections (IFIs). Neutrophil engraftment occurred in 90% of sCBT (n = 77) and 94% sCBT + TPDCD34+ (n = 71) recipients at a median of 23 and 12 days post transplantation, respectively (P < 0.01). RESULTS: The 4-year IRM was 24% and 20%, respectively (P = 0.7), with no differences at day +30 (5% and 4%, respectively) and day +100 (10% and 8%, respectively). In multivariate analysis early status of the underlying malignancy, cytomegalovirus (CMV)-seronegative recipient and high CD34+ cell content in the cord blood unit before cryostorage (≥1.4 × 10(5) /kg) were protective of IRM. Among the causes of IRM, bacterial infections and IFIs were more common in sCBT (15% vs. 4%), while CMV disease and parasitic infections were more common in the sCBT + TPDCD34+ cohort (5% vs. 16%). CONCLUSION: These data show that sCBT supported with TPDCD34(+) cells results in much shorter periods of post-transplant leukopenia, but the short- and long-term rates of IRM were comparable to those of sCBT, presumably because immune recovery is equally delayed in both graft types.


Asunto(s)
Infecciones Bacterianas/epidemiología , Trasplante de Células Madre de Sangre del Cordón Umbilical/métodos , Inmunosupresores/uso terapéutico , Leucemia/terapia , Linfoma/terapia , Micosis/epidemiología , Agonistas Mieloablativos/uso terapéutico , Trasplante de Células Madre de Sangre Periférica/métodos , Virosis/epidemiología , Adolescente , Adulto , Antígenos CD34 , Infecciones Bacterianas/mortalidad , Busulfano/uso terapéutico , Estudios de Cohortes , Ciclosporina/uso terapéutico , Femenino , Factor Estimulante de Colonias de Granulocitos/uso terapéutico , Humanos , Masculino , Persona de Mediana Edad , Análisis Multivariante , Micosis/mortalidad , Estudios Retrospectivos , Factores de Riesgo , Índice de Severidad de la Enfermedad , Tiotepa/uso terapéutico , Acondicionamiento Pretrasplante/métodos , Vidarabina/análogos & derivados , Vidarabina/uso terapéutico , Virosis/mortalidad , Irradiación Corporal Total , Adulto Joven
3.
Transpl Infect Dis ; 14(5): 496-501, 2012 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-22548804

RESUMEN

Toxoplasmosis is a devastating opportunistic infection that can affect immunocompromised patients such as cord blood transplantation (CBT) recipients. The clinical characteristics of 4 toxoplasmosis CBT patients treated at our institution are reviewed, together with 5 cases collected from the literature. The rate of toxoplasmosis in our hospital was 6% in CBT recipients and 0.2% in other types of allogeneic hematopoietic stem cell transplantation (P < 0.001). Five patients (56%) presented disseminated toxoplasmosis and 4 patients (44%) had localized infection in the central nervous system. In 5 of the 9 patients considered (56%), cytomegalovirus viral replication had been detected before the clinical onset of toxoplasmosis. Seven patients (78%) had previously developed graft-versus-host disease. All patients who exhibited disseminated disease died due to Toxoplasma infection. Pre-transplant serology was positive in 1 patient, negative in 3 patients, and not performed in another. Only 1 of these 5 patients with disseminated disease had received Toxoplasma prophylaxis with cotrimoxazole. It could be concluded that mortality in CBT patients with disseminated toxoplasmosis is unacceptably high. The negative results of serology in the majority of these cases, and its unspecific clinical presentation, makes diagnosis exceedingly difficult. Better diagnostic tests and prophylaxis strategy are needed in CBT recipients.


Asunto(s)
Trasplante de Células Madre de Sangre del Cordón Umbilical/efectos adversos , Infecciones Oportunistas/epidemiología , Toxoplasma/aislamiento & purificación , Toxoplasmosis/epidemiología , Adolescente , Adulto , Niño , Infecciones por Citomegalovirus/complicaciones , Infecciones por Citomegalovirus/epidemiología , Femenino , Enfermedad Injerto contra Huésped/epidemiología , Humanos , Masculino , Persona de Mediana Edad , Infecciones Oportunistas/mortalidad , Infecciones Oportunistas/parasitología , Toxoplasma/genética , Toxoplasmosis/mortalidad , Toxoplasmosis/parasitología , Adulto Joven
4.
Arch Soc Esp Oftalmol ; 91(11): 513-519, 2016 Nov.
Artículo en Inglés, Español | MEDLINE | ID: mdl-27311989

RESUMEN

OBJECTIVE: To evaluate the usefulness of a semiautomatic measuring system of arteriovenous relation (RAV) from retinographic images of hypertensive patients in assessing their cardiovascular risk and silent brain ischemia (ICS) detection. METHODS: Semi-automatic measurement of arterial and venous width were performed with the aid of Imedos software and conventional fundus examination from the analysis of retinal images belonging to the 976 patients integrated in the cohort Investigating Silent Strokes in Hypertensives: a magnetic resonance imaging study (ISSYS), group of hypertensive patients. All patients have been subjected to a cranial magnetic resonance imaging (RMN) to assess the presence or absence of brain silent infarct. RESULTS: Retinal images of 768 patients were studied. Among the clinical findings observed, association with ICS was only detected in patients with microaneurysms (OR 2.50; 95% CI: 1.05-5.98) or altered RAV (<0.666) (OR: 4.22; 95% CI: 2.56-6.96). In multivariate logistic regression analysis adjusted by age and sex, only altered RAV continued demonstrating as a risk factor (OR: 3.70; 95% CI: 2.21-6.18). CONCLUSIONS: The results show that the semiautomatic analysis of the retinal vasculature from retinal images has the potential to be considered as an important vascular risk factor in hypertensive population.


Asunto(s)
Infarto Encefálico/epidemiología , Hipertensión/complicaciones , Procesamiento de Imagen Asistido por Computador/métodos , Vasos Retinianos/patología , Retinoscopía/métodos , Anciano , Arteriolas/patología , Automatización , Infarto Encefálico/etiología , Femenino , Fondo de Ojo , Humanos , Hipertensión/patología , Masculino , Persona de Mediana Edad , Análisis Multivariante , Medición de Riesgo , Factores de Riesgo , Programas Informáticos , Vénulas/patología
5.
Exp Hematol ; 27(2): 380-5, 1999 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-10029178

RESUMEN

Cost-efficient umbilical cord blood (UCB) banking requires well-standardized methods of volume reduction and storage. To compare UCB fractionation using a technique of hydroxyethyl starch (HES) sedimentation with the Ficoll (double) and Percoll methods, 50 whole units was allocated randomly to each procedure. HES resulted in a significantly better recovery of mononuclear cells (87.5%), granulocyte/macrophage colony-forming units (CFU-GM) (88.4%), and CD34- cells (87.4%) and lesser volume reduction (85.5%). HES was the least laborious, time consuming, and expensive of the three procedures, costing 3.4- and 4.4-fold less than the Ficoll and Percoll methods, respectively. Five units processed by each method was frozen in 4.5-mL cryotubes under optimal conditions. After thawing, the greatest degree of recovery of viable nucleated cells and number of CFU-GM per unit were obtained using the HES procedure. Using 4.5-mL cryotubes, the calculated number of units that could be stored in 600-L containers was 3.8- and 2.2-fold higher for Ficoll- and Percoll-separated than for HES-separated units, respectively. Nevertheless, the higher direct costs of the density gradient separation procedures outweighed their lower storage cost. For long-term cryopreservation, we assessed the freezing of HES-processed units in 50-mL cryobags and their specifically designed canisters. We found cell recoveries similar to those obtained with cryotubes, but storage capacity was decreased. Special racks designed for these canisters resulted in a 5-fold increase over the number of units stored in standard cryobags. This system also is feasible for Percoll- and Ficoll-separated units, resulting in comparable storage costs for the three separation methods. We conclude that this HES procedure and the 50-mL cryobags constitute a cost-efficient system for large-scale UCB banking.


Asunto(s)
Conservación de la Sangre/métodos , Movilización de Célula Madre Hematopoyética/métodos , Trasplante de Células Madre Hematopoyéticas , Supervivencia Celular , Sangre Fetal , Humanos , Trasplante Homólogo
6.
Bone Marrow Transplant ; 20(4): 305-6, 1997 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-9285545

RESUMEN

Thrombotic microangiopathy (TMA) is an infrequent but serious complication of allogeneic transplantation. The success rate of plasma exchange (PE) reported in the treatment of this entity is a controversial subject. We report the outcome of 10 patients with TMA post-allogeneic transplantation after treatment with PE. Two out of the 10 patients have not responded, five had a partial response, but died of acute GVHD or interstitial pneumonitis, and three have responded and recovered. Our study suggests that there are different degrees of TMA severity. Only mild multifactorial cases with no severe hemolysis (LDH activity <1000 U/l) may be fully resolved with PE.


Asunto(s)
Trasplante de Médula Ósea/efectos adversos , Intercambio Plasmático , Trombosis/etiología , Adolescente , Adulto , Ciclosporina/efectos adversos , Femenino , Humanos , Masculino , Trombosis/terapia , Trasplante Homólogo
7.
Bone Marrow Transplant ; 17(6): 1175-8, 1996 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-8807132

RESUMEN

A 15-year-old, 50 kg weight patient with CML had a myeloblastic transformation which reverted to Ph negative remission with intensive chemotherapy 5 years after diagnosis. Umbilical cord blood (UCB) from an HLA-haploidentical sister had been frozen 2 years and 9 months before, as she had no HLA-identical sibling and no suitable unrelated donor had been found. UCB transplant was selected on the basis of previous general experience with this kind of transplant, lack of a better choice of donor, and likelihood of a prompt relapse of the disease without delay and the patient developed grade II aGVHD as well as severe CsA toxicity which required discontinuation of the drug, anti-IL2r being given instead. Subsequently she only had histologic evidence of cGVHD and 1.5 years after the transplant she remains in complete hematologic remission with full chimerism and without evidence of the bcr/abl fusion gene. This case illustrates further possibilities of allo-transplantation using UCB.


Asunto(s)
Células Sanguíneas/trasplante , Sangre Fetal/citología , Leucemia Mielógena Crónica BCR-ABL Positiva/terapia , Adolescente , Femenino , Haplotipos , Humanos , Trasplante Homólogo
8.
Bone Marrow Transplant ; 21(11): 1097-9, 1998 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-9645571

RESUMEN

One of the concerns about the use of cord blood as a source of hematopoietic stem cells for allogeneic transplantation is the possibility of contamination by maternal cells which could cause life-threatening GVHD. We have assessed cord blood contamination using PCR analysis of several minisatellite regions to detect maternal DNA. Eighty mother-cord pairs were obtained for this study. In one case there were no specific maternal alleles at any loci and, therefore, cord blood could not be evaluated. Thus, there was a total of 79 informative cases for the detection of maternal cells in the fetal circulation. In most cases, the level of detection was between 0.5 and 1%. We detected maternal DNA in the cord blood sample in only one case (1.26%), and the analysis of dilution experiments led to an estimate of 0.5-1% maternal cells. In conclusion, using PCR amplification of hypervariable regions, maternal DNA is very rarely detected in the cord blood collected at birth, although this approach has a relatively low level of sensitivity.


Asunto(s)
ADN/sangre , ADN/genética , Sangre Fetal/química , Repeticiones de Minisatélite , Reacción en Cadena de la Polimerasa/métodos , Quimera/genética , Quimera/inmunología , Femenino , Sangre Fetal/citología , Genotipo , Enfermedad Injerto contra Huésped/etiología , Trasplante de Células Madre Hematopoyéticas/efectos adversos , Humanos , Recién Nacido , Intercambio Materno-Fetal/genética , Intercambio Materno-Fetal/inmunología , Reacción en Cadena de la Polimerasa/estadística & datos numéricos , Embarazo , Sensibilidad y Especificidad , Trasplante Homólogo
9.
Bone Marrow Transplant ; 22(8): 817-8, 1998 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-9827982

RESUMEN

A 24-year-old male developed cytogenetic relapse of chronic myeloid leukemia (CML) four years after allogeneic BMT. After a year of treatment with IFN-alpha, he achieved a partial cytogenetic response. Treatment with donor leukocyte infusions (DLI) was given (total dose 1 x 10(8) T lymphocytes/kg). Two months later, he developed acute GVHD (skin and liver), that improved with CsA and methylprednisolone and resulted in cytogenetic remission with complete donor chimerism. One month later he developed rhinocerebral mucormycosis and was successfully treated with surgical debridement and liposomal amphotericin B (total dose 12 g). This is the first case of mucormycosis described after DLI.


Asunto(s)
Anfotericina B/uso terapéutico , Antifúngicos/uso terapéutico , Leucemia Mielógena Crónica BCR-ABL Positiva/terapia , Transfusión de Leucocitos/efectos adversos , Mucormicosis , Adulto , Encefalopatías/tratamiento farmacológico , Encefalopatías/etiología , Encefalopatías/microbiología , Encefalopatías/cirugía , Portadores de Fármacos , Humanos , Liposomas , Masculino , Mucormicosis/tratamiento farmacológico , Mucormicosis/etiología , Mucormicosis/cirugía , Trasplante Homólogo
10.
Bone Marrow Transplant ; 25(10): 1105-8, 2000 May.
Artículo en Inglés | MEDLINE | ID: mdl-10828874

RESUMEN

A 48-year-old patient with IgA k multiple myeloma received a BMT from his HLA-matched sibling. After transplantation, the disease relapsed. Melphalan therapy followed by reinfusion of haemopoietic blood stem cells collected from the patient led to the improvement of the clinical status, although mixed chimerism and an elevated serum IgA persisted. Successful donor immunisation against an immunogenic preparation of the recipient monoclonal protein was performed before the infusion of donor T lymphocytes (DLI) into the patient. Ten weeks after the lymphocyte infusions, no monoclonal band was evidenced and donor complete chimerism was detected. The patient did not develop GVHD. Once complete remission was achieved, the idiotype vaccine was administered to the patient. Nineteen months after DLI, the patient remains in remission. Bone Marrow Transplantation (2000).


Asunto(s)
Donantes de Sangre , Inmunización , Inmunoglobulina A/inmunología , Idiotipos de Inmunoglobulinas/inmunología , Cadenas kappa de Inmunoglobulina/inmunología , Inmunoterapia Adoptiva , Transfusión de Linfocitos , Mieloma Múltiple/terapia , Proteínas de Mieloma/inmunología , Terapia Recuperativa , Linfocitos T/trasplante , Antineoplásicos Alquilantes/uso terapéutico , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Trasplante de Médula Ósea , Quimera , Terapia Combinada , Dexametasona/administración & dosificación , Doxorrubicina/administración & dosificación , Supervivencia de Injerto , Humanos , Masculino , Melfalán/uso terapéutico , Persona de Mediana Edad , Mieloma Múltiple/tratamiento farmacológico , Mieloma Múltiple/inmunología , Inducción de Remisión , Vincristina/administración & dosificación
11.
Bone Marrow Transplant ; 28(4): 355-63, 2001 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-11571507

RESUMEN

The number of infused cells is a very important factor in cord blood transplant (CBT) engraftment. Prior ex vivo expansion of aliquots of transplanted cord blood (CB) units is being investigated as a procedure to increase engraftment potential, but results are difficult to evaluate due to a lack of markers for assessing the contribution of expanded cells. We transplanted five patients, infusing the best available CB unit and cells from a second donor simultaneously. In two patients, these cells were obtained from another frozen CB unit by CD34(+)positive selection and culture expansion; the other three patients received uncultured highly purified haploidentical CD34(+) cells. The first two patients had DNA from the culture expanded CB cells detected only for a few days around day +11 when the absolute neutrophil count (ANC) was >200/microl; thereafter and when the ANC was <500/microl, only donor DNA from the uncultured CB was detected. For the other three patients, DNA analysis showed early and transient granulocyte engraftment of haploidentical cells, progressively replaced by the CB-derived granulocytes. We concluded that: (1) simultaneous infusion of lymphocyte-depleted HLA highly mismatched haematopoietic progenitor cells has not produced unfavourable effects for CBT; (2) the double transplant model is suitable for evaluating the engraftment potential of ex vivocultured CB cells in the clinical setting; (3) the culture conditions used did not result in early recovery of ANC; and (4) co-transplantation of purified uncultured HLA haploidentical CD34(+) cells may reduce the time of neutropenia following CBT.


Asunto(s)
Sangre Fetal/citología , Rechazo de Injerto/genética , Haplotipos/genética , Trasplante de Células Madre Hematopoyéticas/métodos , Neutrófilos/citología , Neutrófilos/metabolismo , Núcleo Familiar , Polimorfismo Genético/genética , Enfermedad Aguda , Adulto , Separación Celular/métodos , Células Cultivadas , Femenino , Rechazo de Injerto/inmunología , Trasplante de Células Madre Hematopoyéticas/efectos adversos , Humanos , Leucemia Mieloide/genética , Leucemia Mieloide/terapia , Masculino , Persona de Mediana Edad , Quimera por Trasplante/genética
12.
Bone Marrow Transplant ; 17(3): 439-41, 1996 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-8704703

RESUMEN

A 24-year-old man with acute myelomonocytic leukemia (AML-M4) who relapsed 6 months after an allogeneic BMT was treated with chemotherapy followed by donor leukocyte infusions (4.19 x 10(8) mononuclear cells/kg). The patient developed grade II acute GVHD that responded to therapy with CsA and prednisone. Chimerism was assessed by PCR amplification of the MCT 118 hypervariable region. Fourteen months after donor leukocyte infusions the patient remains in complete remission, without any morphologic and cytogenetic evidence of leukemia, and with a complete donor chimerism. This case shows that donor leukocyte infusions are an effective therapy for some acute myeloid leukemia patients who relapse after allogeneic BMT.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Donantes de Sangre , Trasplante de Médula Ósea , Leucemia Mielomonocítica Aguda/terapia , Transfusión de Leucocitos , Adulto , Terapia Combinada , Enfermedad Injerto contra Huésped , Antígenos HLA/genética , Humanos , Masculino , Recurrencia
13.
Rev Esp Cardiol ; 54(1): 117-9, 2001 Jan.
Artículo en Español | MEDLINE | ID: mdl-11252245

RESUMEN

The case of a 62-year-old diabetic and smoker male who was under study in another hospital due to anemia, thrombopenia and hematuria of several months of evolution is presented. The patient was admitted to the coronary unit for an acute extensive transmural myocardial infarction and treated with t-PA. A few hours later the patient presented hematuric urine, a decrease in hemoglobin and platelets and acute renal insufficiency. Hematologic study confirmed the diagnosis of paroxystic nocturnal hemoglobinuria. The evolution of the patient was poor despite intensive medical treatment requiring hemodialysis. The patient presented cardiac tamponade and died. The role of hematologic disease in acute myocardial infarction and the treatment and evolution of the coronary syndrome in the context of the disease are discussed.


Asunto(s)
Hemoglobinuria Paroxística/complicaciones , Infarto del Miocardio/etiología , Humanos , Masculino , Persona de Mediana Edad
15.
Rev Clin Esp (Barc) ; 214(9): 505-12, 2014 Dec.
Artículo en Inglés, Español | MEDLINE | ID: mdl-25087090

RESUMEN

BACKGROUND AND OBJECTIVES: Atrial fibrillation (AF) is the most common type of arrhythmia. The purpose of this study was to determine the prevalence of atrial fibrillation and its relationship with cardiovascular risk factors in Spain. METHODOLOGY: Cross-sectional study based on a grouped analysis of 17,291 randomized individuals recruited in 6 population studies. RESULTS: The prevalence of atrial fibrillation was 1.5% (95% CI:1.3-1.7%). Men had a greater prevalence of the disease than women (1.9 vs. 1.1%, respectively). The prevalence of atrial fibrillation progressively increased with age: 0.05% for patients younger than 45 years, 0.5% for those between 45-59 years of age, 2.3% for those between 60-74 years of age and 6.3% for those older than 75 years. The percentage of individuals who were underwent anticoagulant treatment was 74.3%. The risk factors significantly associated with arrhythmia were an age older than 60 years (odds ratio [OR]: 7.6; 95% CI: 5.1-11.2), the male sex (OR:1.8; 95% CI: 1.4-2.4), arterial hypertension (OR:1.6; 95% CI: 1.2-2.1), obesity (OR:1.5; 95% CI:1.2-2.1) and a history of coronary artery disease (OR:1.9; 95% CI: 1.3-3.0). CONCLUSION: Atrial fibrillation is a common disease in elderly individuals, while its prevalence is low in individuals younger than 60 years. Most individuals with atrial fibrillation were on anticoagulant treatment. The risk factors for this type of arrhythmia are age, the male sex, hypertension, obesity and a history of coronary artery disease.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA